Corbus announces dosing of first patient in Phase 1 trial of CRB-701

Corbus Pharmaceuticals announced the first patient in the U.S. has been dosed in the Phase 1 clinical trial of CRB-701, a next-generation antibody-drug-conjugate targeting Nectin-4. “The initiation of our clinical trial is a significant milestone for Corbus and builds on the encouraging CRB-701 data presented by our development partner CSPC Pharmaceutical Group at ASCO-GU 2024 from the phase 1 study in China,” said Yuval Cohen, PhD. Chief Executive Office of Corbus. “Those data suggest CRB-701 has a differentiated PK and safety profile compared to PADCEV which could translate into meaningful clinical benefits for patients with mUC and other Nectin-4 positive solid tumors.”